Alnylam Signs Billion Dollar RNAi Deal With Roche
This article was originally published in The Pink Sheet Daily
Executive Summary
Best path to build value for shareholders is to maintain independent, focused and hungry biotech culture, Alnylam CEO tells “The Pink Sheet” DAILY.
You may also be interested in...
Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.
Alnylam CEO John Maraganore - An Interview With "The Pink Sheet" DAILY (Part 1 of 2)
CEO of the RNAI pioneer firm talks about life after the Roche collaboration and how its partnership with Takeda is different.
Roche Keeps Shopping: Mirus Acquisition Bolsters RNAi Portfolio
Firm will pay $125 million for access to Wisconsin-based Mirus’ Dynamic PolyConjugates technology.